| Name | Title | Contact Details |
|---|
Biosign Technologies Inc. engages in the development, manufacture, and sale of medical devices and information systems. The company provides cloud based systems for non-invasive monitoring of common health risks associated with blood pressure, life style, and medication. Its analysis and reporting tools give patients and their healthcare team access to real-time health information for treatment planning, evaluation, and management. The company offers UFIT, an automated wrist sphygmography system with computer controls that measures various signs, including blood pressure, mean arterial pressure, pulse rate, and pulse rate variability from a single digital signal acquired passively with an inflatable cuff at the wrist. It also provides Healthanywhere, a software-based, remote patient monitoring application that runs on Windows PC and Blackberry platforms. Healthanywhere solution provides for the continuum of care from wellness promotion to self-managed care, including monitoring of chronic diseases, such as congestive heart failure, hypertension, diabetes, asthma, and obesity. Biosign Technologies Inc. was incorporated in 2004 and is headquartered in Thornhill, Canada.
The Sibery Group LLC is a Oak Brook, IL-based company in the Healthcare, Pharmaceuticals, & Biotech sector.
Creganna-Tactx Medical is a Minneapolis, MN-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
WAVE Life Sciences is utilizing its innovative and proprietary synthetic chemistry drug development platform to design, develop and commercialize stereopure nucleic acid therapeutics that precisely target the underlying cause of rare genetic diseases, delivering exceptional treatment options for patients. Given the unique versatility of its chemistry platform, WAVE`s pipeline will span multiple oligonucleotide modalities including antisense, exon-skipping and single-stranded RNAi.
Foresee is a Taiwan and US-based biopharmaceutical company listed on the Taipei Exchange (6576.TWO). Foresee`s R&D efforts are focused in two key areas, namely its unique stabilized injectable formulation (SIF) depot delivery technology with derived drug products targeting specialty markets, and secondly its transformative preclinical and clinical first-in-class NCE programs targeting rare and severe disease areas with high unmet needs. Foresee`s product portfolio includes late stage and early stage programs. CAMCEVI® 42 mg is now approved in the U.S. and under regulatory review in the EU. Additionally, U.S. and EU regulatory submissions are in preparation for CAMCEVI® 21 mg. FP-025 – a highly selective oral MMP-12 inhibitor targeting inflammatory and fibrotic diseases, currently in Phase 2/3 studies, including a Phase 2/3 study for COVID-19 virus-induced acute respiratory distress syndrome (ARDS). FP-045 – a highly selective oral small molecule allosteric activator of ALDH2, a mitochondrial enzyme, for which a Phase 1b/2 study is currently planned for Fanconi Anemia.